Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anfoleish for Uncomplicated Cutaneous Leishmaniasis
NCT01845727Phase 2Completed
- Sponsor
- Drugs for Neglected Diseases initiative
- Start
- Feb 2014
- Primary completion
- May 2016
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of amphotericin B liposomal in cutaneous leishmaniasis (CL), sponsored by Drugs for Neglected Diseases initiative. Started Feb 2014; status: completed.
02
Drugs
amphotericin B liposomal
03
Conditions
cutaneous leishmaniasis (CL)
Beyond the preview
Go deeper on NCT01845727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01845727.